ISTH Congress Abstracts

Official abstracts site for the ISTH Congress

MENU 
  • Home
  • Congress Archive
    • ISTH 2022 Congress
    • ISTH 2021 Congress
    • ISTH 2020 Congress
  • Resources
  • Search

ISTH 2021 Congress

July 17-21, 2021. Philadelphia, PA.

View by Title View by Number View Themes
Jump to:  View All • a b c d e f g h i j k l m n o p q [r] s t u v w x y z
  • Abstract Number: PB0556

    Randomized Clinical Trial of PK-guided Treatment of Desmopressin Combined with FVIII Concentrate versus Only FVIII Concentrate in Peri-operative Hemophilia A Patients: Final Results of the Little DAVID Study

    L.G.R. Romano1, L.M. Schütte1, R.M. van Hest2, K. Meijer3, B.A.P. Laros - van Gorkom4, F.C.J.I. Heubel-Moenen5, M.H.E. Driessens6, S. Polinder7, M.H. Cnossen8, F.W.G. Leebeek1, R.A.A. Mathôt2, M.J.H.A. Kruip1, On behalf of the SYMPHONY Consortium

  • Abstract Number: PB0969

    Rapid and Complete Clearance of HPA-1a Mismatched Platelets in a Human Model of Fetal and Neonatal Alloimmune Thrombocytopenia by a Hyperimmune Plasma Derived Polyclonal Anti HPA-1a Antibody

    C. Geisen1, E. Fleck1, S.M.G. Schäfer2, C. Walter2, S. Braeuninger1, K. Olsen3, Z. Bhagwagar4, A. Mortberg5, A. Wikman5,6, M. Kjaer7,8, J. Kjeldsen-Kragh9,10, F. Behrens2, E. Seifried1, M. Köhm2

  • Abstract Number: PB0049

    Rapid Detection of DOACs in DVT Patients Using a Single-use Microfluidic Chip under Whole Blood Flow

    J.M. Rossi1, K.A. Panckeri2, A.C. Cuker2, S.L. Diamond1

  • Abstract Number: PB1035

    Rapid Internalization and Nuclear Translocation of CCL5 and CXCL4 in Endothelial Cells

    A. Dickhout1, M.A. van Zandvoort1, R.R Koenen1

  • Abstract Number: PB0708

    Rare Bleeding Disorders in Children. Towards Establishing a Local Registry

    D. Florinskiy1, D. Fedorova1, A. Poletaev1, E. Seregina1, A. Pshonkin1, P. Zharkov1

  • Abstract Number: PO187

    Rare Complications of DOAC Treatment

    M. Hulikova1, S. Hulik2, J. Hulikova1

  • Abstract Number: PB0037

    Rat Model of Metabolic Disorders: Dynamics of Hemostasis and Endothelial Function Changes

    T. Obergan1, L. Lyapina1, M. Grigorjeva1, T. Shubina1

  • Abstract Number: PB0609

    Rationale and Design of the “International Registry on the Symptomatic Hemophilia A/B Carriers”

    S. Pasca1, R. Sidonio Jr.2, E. Grandone3, E. Zanon1, M. Othman4

  • Abstract Number: PB0564

    Real World Data on Haemophilia A Patients Switching to rFVIIIFc Treatment in Greece. Interim Results from the Multicenter Observational Study TOOL

    O. Katsarou1, A. Kouramba1, E. Nomikou2, G. Kampelos2, S. Vakalopoulou3, H. Moka3, M. Economou4, V. Gourtsa4, E. Michalopoulou5, H. Pergantou5

  • Abstract Number: PO164

    Real World Experience Use of DOAC in APLS Patients

    Y.Y. Yap1, R.b. Ramli1, J. Suriar2, J. Sathar1

  • Abstract Number: PB0637

    Real World Experience with Emicizumab with Hemophilia A Treated in Private Practice in Mexico

    M.T. Pompa Garza1, A. Arias Aranda2, R. Miranda Madrazo3, N. Padilla Duron4, C.S. Gómez González5

  • Abstract Number: PB0577

    Real-world Annual Bleeding Rate in People with Severe Hemophilia A without Inhibitor on Prophylaxis, Comparing Switched to rFVIII-Fc versus Non-switched Patients: A Multicentre, Retrospective, Non interventional, before-after Study with the French BERHLINGO Database (MOTHIF-II)

    V. Horvais1, N. Drillaud1, M. Sigaud1, M. Fouassier1, C. Ternisien1, Y. Repesse2, B. Guillet3, S. Bayart3, P. Beurrier4, L. Ardillon5, Y. Gruel5, J.-B. Valentin5, S. Bauer6, B. Pan-Petesch7, V. Cussac8, J. Rose8, M. Pennetier1, M. Trossaërt1, BERHLINGO Group

  • Abstract Number: PB0452

    Real-world Clinical and Patient-centric Outcomes in People with Haemophilia A in France: Findings from the CHESS II Study

    A. Shaikh1, T. Burke1,2, C. Hawes3, G. Duport4, J. O'Hara1,2, C. Camp3

  • Abstract Number: PB0487

    Real-world Clinical and Patient-centric Outcomes in People with Haemophilia A in Germany: Findings from the CHESS II Study

    A. Shaikh1, T. Burke1,2, C. Hawes3, T. Becker4, S. Brandt4, J. O'Hara1,2, C. Camp3

  • Abstract Number: PB0464

    Real-world Clinical and Patient-centric Outcomes in People with Haemophilia A in Italy: Findings from the CHESS II Study

    A. Shaikh1, T. Burke1,2, C. Hawes3, A. Lupi4, J. O'Hara1,2, C. Camp3

  • Abstract Number: PB0456

    Real-world Clinical and Patient-centric Outcomes in People with Haemophilia A in Spain: Findings from the CHESS II Study

    A. Shaikh1, T. Burke1,2, C. Hawes3, J. O'Hara1,2, C. Camp3

  • Abstract Number: PB0479

    Real-world Clinical and Patient-centric Outcomes in People with Haemophilia A in the United Kingdom: Findings from the CHESS II Study

    A. Shaikh1, T. Burke1,2, C. Hawes3, W. McKeown4, D. Morgan4, J. O'Hara1,2, C. Camp3

  • Abstract Number: PB1252

    Real-world Data on the Use of Oral Anticoagulants for the Treatment of Venous Thromboembolism in Sweden: Oral Anticoagulant Use and Baseline Characteristics from the Venous Thromboembolism Treatment Study

    A. Gottsäter1, H. Pohjantähti-Maaroos2, K. Bokenberger3, S. Graham4, A. Jenkins5, D. Lambrelli4, K. Mercaldi6, M. Raluy3, W. Ghanima7

  • Abstract Number: PB0099

    Real-world Effectiveness of BAY 94-9027 to Treat Hemophilia A in the ATHNdataset

    C. He1, M. Chandler1, M. Recht1, J. Charlet2, T. Moulton2, P. Vashi2

  • Abstract Number: PB0537

    Real-world Experience in Introducing Emicizumab Prophylaxis for Adults with Haemophilia A without Inhibitors

    N. Larkin1, E. Singleton1, J. Benson1, N. Boland1, J. Cleary1, S. Brady1, D. Gorman1, N. Flynn1, F. Ryan1, M. Mc Gowen1, S. Roche1, C. Bergin1, B. Mary1, K. Ryan1, M. Lavin1, J.S O Donnell1, N. O Connell1

  • Abstract Number: PB0677

    Real-world Experience of Emicizumab Treatment Using Entire Vials Only

    K. Fischer1, A.A. Donners1, R.T Urbanus1, I.C. Kremer Hovinga1, L.F. van Vulpen1, P.R van der Valk1, K.P. van Galen1, N. Uitslager1, R.E. Schutgens1

  • Abstract Number: PB0645

    Real-world Experience of rIX-FP Prophylaxis at Dosing Intervals of up to 14 Days in a Pediatric Patient with Hemophilia B during the COVID-19 Pandemic

    B.L. Díaz Jordan1, T. Cebanu2, M.T. Álvarez Román2

  • Abstract Number: PB0550

    Real-world Joint Bleeding Rates in Patients with Congenital Hemophilia and Inhibitors: Final Data from the FEIBA Global Outcome (FEIBA GO) Study

    J. Windyga1, C. Hermans2, P.A. Holme3, C. Escuriola-Ettingshausen4, A.R. Cid5, K. Khair6, J. Oldenburg7, J. Botha8, N. Kemenyash8, M. Kokot-Kierepa8, C. Négrier9

  • Abstract Number: PB0463

    Real-world Outcomes in People with Severe Hemophilia B Receiving FIX Prophylaxis across Europe: A CHESS II Analysis

    T. Burke1,2, S. Asghar1, J. O'Hara1,2, M. Chuang3, E. Sawyer3, N. Li3

  • Abstract Number: PB0551

    Real-world Usage of rFIXFc in Sweden: A Report from the Swedish National Registry for Bleedings Disorders

    A. Olsson1, L. Myrin-Westesson1, F. Baghaei1, M. Holmström2,3, E. Olsson2, M. Magnusson2,4,5, S. Ranta4, J. Astermark6, N. Gretenkort Andersson7, J. Thanner8, J. Szamosi8, K. Sennfält8

  • Abstract Number: OC 08.4

    Real-world Use of Damoctocog Alfa Pegol in Patients with Hemophilia A: Analysis of PK Profiles and Treatment Regimen Data from the WAPPS-Hemo Database

    M.E. Mancuso1, P. Chelle2, E. Iserman3, T. Matthew3, A. Keepanasseril3, A. Edginton2, A. Iorio3,4, WAPPS-Hemo Investigators

  • Abstract Number: PB0501

    Real-world Use of FVIII in People with Severe Hemophilia A without Inhibitor on Prophylaxis, Comparing Switched to rFVIII-Fc versus Non-switched Patients: A Multicentre, Retrospective, Non Interventional, before-after Study with the French Nationwide Claims Database (MOTHIF-II)

    V. Horvais1, N. Drillaud1, M. Sigaud1, M. Fouassier1, C. Ternisien1, Y. Repesse2, B. Guillet3, S. Bayart3, P. Beurrier4, L. Ardillon5, Y. Gruel5, J.-B. Valentin5, S. Bauer6, B. Pan-Petesch7, V. Cussac8, J. Rose8, M. Pennetier1, M. Trossaërt1, BERHLINGO Group

  • Abstract Number: PB0946

    Reclassification of von Willebrand Disease Classification and Effects of Vascular Dysfunction on von Willebrand Factor

    H. Watson1, Y.E. Ng2

  • Abstract Number: LPB0006

    Recombinant Heparin: An Old Drug for the Modern World

    B.E. Thacker1, K. Thorne1, C. Cartwright1, J. Park1, K. Glass1, A. Chea1, J.D. Esko2, W. Jeske3, J.M. Walenga3, C.A. Glass1

  • Abstract Number: PB0605

    Recommendations for Intramuscular COVID-19 Vaccination in Patients with Hemophilia

    C. Pfrepper1, K. Holstein2, C. Koenigs3, C. Heller3, M. Krause4, M. Olivieri5, C. Bidlingmeier5, M. Sigl-Kraetzig6, J. Wendisch7, R. Klamroth8, S. Halimeh9, J. Oldenburg10, S. Horneff10, H. Richter11, I. Wieland12, A. Tiede12

  • Abstract Number: OC 45.4

    Recovery of BAY 94-9027 [Jivi®] with One-stage Clotting and Chromogenic Assays: A Multicentre Study

    P. Meijer1, D. Adcock2, M Hollestelle1, R. Marlar3

  • Abstract Number: PB1199

    Recurrence and Mortality Following First Venous Thromboembolism among Saudi Population: Single-centre Cohort Study

    F. Aleidan1, R. Almanea1, N. Shalash1, N. Alrajhi1, A. Almoneef1, S. Almousa1, K. Abuelgasim1

  • Abstract Number: PB1242

    Recurrent Thromboembolic Risk in Paroxysmal Nocturnal Hemoglobinuria Patients not on Anticoagulation Treated with Terminal Complement Inhibition

    G. Gerber1, A. DeZern1, S. Chaturvedi1, R. Brodsky1

  • Abstract Number: PO124

    Recurrent Thrombosis and Antithrombin Deficiency

    L. Stanciakova1, P. Holly1, J. Palova1, M. Brunclikova1, M. Dobrotova1, T. Bolek2, M. Samos2, P. Kubisz1, J. Stasko1

  • Abstract Number: PB1273

    Recurrent Thrombosis Rescued by Fondaparinux in High-risk Patients: Case Series and Review of Literature

    M. Tanguay1, C. Séguin2

  • Abstract Number: PB0582

    Reducing the Time of HAL and pedHAL Assessment

    I.A. Kuijlaars1, J. van der Net2, V. Bouskill3, P. Hilliard4, A. Juodyte5, K. Khair6, R.E. Schutgens1, S.S. Trakymiene5, K. Fischer1

  • Abstract Number: PB0115

    Refining and Validating a Model of FXI Activation and Activity in Thrombin Generation and Blood Coagulation

    H.H.S. Lakshmanan1, A. Estonilo2, C. Puy1, T. J. Zheng1, J. Maddala3, D. Gailani4, J. J. Shatzel1, A. Gruber1, P. L. Jurney2, O. J.T. McCarty1

  • Abstract Number: PB0444

    Refractory Acquired Hemophilia A (Even More) Complicated with SARS-CoV-2 Infection

    C. Gomez del Castillo Solano1, M. Fernández Docampo1, T. Lado Cives1, M.T. Fernández Fernández1, D. Martínez Señarís1, A. Hevilla Carmona1, M.F. López Fernández1

  • Abstract Number: PB0824

    Refractory Immune Thrombocytopenia (ITP): The Combination of Thrombopoietin Analogs and Immunosuppressants, Experience in a Single Spanish Center

    I. Sánchez Bazán1, S. Martín Téllez1, F.J. López Jaime1, M.I. Muñoz1

  • Abstract Number: PO161

    Refractory Thrombotic Thrombocytopenic Purpura – A Case Report

    A. Aribandi1, C. Ranjith1, S. Sushma2, T. Surapaneni2

  • Abstract Number: PB0711

    Registry of Patients with Congenital Bleeding Disorders from a Single Centre: Clinical and Analytical Characteristics

    A. Lorenzo Jambrina1, A. Torres Tienza1, M. Mosquera Tapia1, S. Marcellini Antonio1, A. García Mateo1, J.A. Queizán Hernández1

  • Abstract Number: OC 16.2

    Regulation of Endothelial Cell Procoagulant Activity by TMEM16 Scramblases

    A. Schmaier1, S. Chen1, K. Sack1, R. Flaumenhaft1, S. Parikh1, S. Schulman1

  • Abstract Number: OC 10.1

    Regulation of P2Y12 Receptor Expression and Activity by cAMP Mediated PKA Signalling in Human Platelets; A Novel Mode of Action of Anti-platelet Drugs?

    J. Khalil1, K. Naseem2, S. Mundell1

  • Abstract Number: PO134

    Reinforcement of Platelets Activity in Patients with Acute Myeloid Leukemia (AML) and Concomitant COVID-19 Infection

    Z. Stupakova1, I. Dyagil1, O. Karnabeda2, H. Menzarar3

  • Abstract Number: PB0298

    Relationship between von Willebrand Factor and Clinical Outcome in Patients with Severe COVID-19

    F. Rivera-Buendia1, L.E. Garcia-Chavez1, E. Cortina-de la Rosa1, F.A. Grimaldo-Gomez1, G.A. Altamirano-Solorzano1, V.M. Anguiano-Alvarez1, M.O. Romero-Arroyo1, R. Izaguirre-Avila1

  • Abstract Number: OC 34.3

    Remote History of Venous Thrombosis and the Risk of Venous Thrombosis beyond the Age of 70 Years

    H. Wang1, F.R Rosendaal1, M. Cushman2, A. van Hylckama Vlieg1

  • Abstract Number: LPB0104

    Resistance to Fibrinolysis in Critically Ill Patients with COVID-19 Can Be Overcome by N-acetylcysteine in vitro

    D. Faille1, M.-C. Bourrienne2, J. Gay1, B. Ho-Tin-Noé2, S. Loyau2, V. Andrieu1, C. Achard1, C. Cavalié1, M. Jandrot-Perrus2, C.V Denis3, S. Ruckly1, J. Patrier1, P.-H. Wicky1, E. de Raucourt4, R. Sonneville1, J.-F. Timsit1, N. Ajzenberg1

  • Abstract Number: PB0803

    Resolution Rates of Provoked Deep Vein Thrombosis and Pulmonary Embolism in Pediatric Patients Managed at a Tertiary Care Center

    M. Dhaliwal1, A. Chan1, M. Bhatt1

  • Abstract Number: OC 13.2

    Response to Treatment for Gastro-intestinal Bleeding in Patients Affected by von Willebrand Disease

    E. Biguzzi1, S.M. Siboni1, S. Braham1, M.T. Pagliari1, F. Peyvandi2

  • Abstract Number: PB0662

    Responses to Anxiety and Depression Items in People with Hemophilia who Tested a Patient Reported Outcome Measure: The coreHEM MH Study

    E. Clearfield1, H.-Y. Chang1, T. Majid2, M.W. Skinner3

  • Abstract Number: OC 18.1

    Result of a Study on Inter-laboratory Variability in the Measurement of Emicizumab and the Interference of Emicizumab in a Variety of Coagulation Tests

    P. Meijer1, M. Hollestelle1, M. de Maat2,1

  • Abstract Number: PB0536

    Results from the Eptacog Beta in the Treatment of Bleeding Episodes of all Severities in Pediatric Hemophilia A or B Patients with Inhibitors

    G. Castaman1, S.W. Pipe2, M. Callaghan3, J. Ducore4, M. Escobar5, C. Hermans6, J. Mahlangu7, U. Nowak-Göttl8, J. Journeycake9, S. Meeks10, M. Recht11, M. Wang12, G. Young13, N. Chambron14, A. AL-Sabbagh15, D. Bonzo15, C. Macie16, I.S. Mitchell17, A. Shapiro18

  • Abstract Number: PB0796

    Results of a Multinational Survey of Diagnosis, Practices and Expertise in the Management of Venous Thromboembolism (VTE) in Pediatric Patients with Sickle Cell Disease (SCD)

    M. Betensky1, R. Kumar2, N.A. Goldenberg3

  • Abstract Number: LPB0138

    Results of a Prospective, Observational, Multi-center Cohort Study of Venous Thromboembolism Outcomes in Thrombocytopenic Cancer Patients (TROVE Study)

    B. Carney1, T.-F. Wang2, S. Ren3, G. George4, A. Al Homssi5, M. Gaddh6, G. Connolly7, V. Shah8, T. Bogue1, A. Bartosic9, D. Neuberg3, L. Baumann Kreuziger10, J. Zwicker1

  • Abstract Number: PB0928

    Results of a Survey Regarding the Diagnosis, Investigation and Management of Unclassified Bleeding Disorders amongst United Kingdom Haemophilia Centre Doctors’ Organisation (UKHCDO) Members

    W. Thomas1, K. Downes1, G. Evans2, G. Gidley3, G. Lowe4, S. MacDonald1, S. Obaji5, J. O'Donnell6, F. Pinto7, M. Desborough8,9

  • Abstract Number: PB1238

    Results of DOAC Dipstick Test in Outpatients with Venous Thromboembolic Disease Are Comparable to Plasma Levels of Direct Oral Inhibitors – An Efficient Assessment Tool

    L. Papageorgiou1,2, J. Harenberg3, S. Auge4, L. Tredler5, I. Elalamy1,2, G. Gerotziafas1,2

  • Abstract Number: PB0472

    Results of Thrombin Generation Assay in Patients Treated with Emicizumab

    B. Baran1, E. Stefanska-Windyga1, A. Buczma1, E. Odnoczko1, J. Windyga2

  • Abstract Number: PB1030

    Resveratrol Prevents Platelet Activation by Inhibition of ROS Formation

    N. Al Arawe1, V. Shpakova2, N. Rukoyatkina2, S. Gambaryan2,1

  • Abstract Number: PB1000

    Reticulated Platelets in Healthy Volunteers. Relationships with Platelet Size Indexes and Platelet Activity

    A. Mazurov1, V. Bodrova1, O. Shustova1, S. Khaspekova1

  • Abstract Number: PB0041

    Reversal of Antithrombotic Effects of FXIa Inhibitor Milvexian (BMS-986177/JNJ-70033093) by Non-specific Agents in a Rabbit AV-shunt Model of Thrombosis

    X. Wang1, Q. Li1, F. Du1, J. Caruso1, A. Nawrocki1, M. Chintala1

  • Abstract Number: PB0040

    Reversal of Oral Anticoagulants: A Survey of Contemporary Practice Trends (ReACT)

    H. Deng1, R. DiDomenico2,3, E. Nutescu2,3

  • Abstract Number: PB1160

    Reversible Factor Xa Inhibitors Specifically Inhibit, in Clot Growth, via the Intrinsic Tenase Complex: A Tool to Determine Specifically the In- and Extrinsic Contribution to Clot Growth

    C. Kluft1, S. Naji1

  • Abstract Number: PB1311

    Review of Intrapartum Management of ITP in Pregnancy in John Radcliffe Hospital

    J. Dhanapal1, S. Pavord1

  • Abstract Number: PB0515

    Reviewing HJHS as a Tool to Assess Outcome Measures in Patients with Haemophilia A in Australia

    S. Parikh1, C. George2, S. McRae3,1, T. Carter2,1, A. Morris2, C. Cramey4, K. McElroy5, H. Tran6,1

  • Abstract Number: PB0335

    Ring Trial for Quality Assurance of the Manual Tilt Tube Technique for Prothrombin Time and INR Determinations in WHO Calibration Laboratories

    A. van den Besselaar1, C. van Rijn1, C. Cobbaert1

  • Abstract Number: OC 12.4

    Risk Factors for Gastrointestinal Bleeding in Patients with Gastrointestinal Cancer Using Edoxaban: Results from the Hokusai VTE Cancer Study

    F.T. Bosch1,2, F.I. Mulder1,2, M.V. Huisman3, J. Zwicker4, M. Di Nisio5, M. Carrier6, A. Segers7, P. Verhamme8, S. Middeldorp9, J.I. Weitz10, M.A. Grosso11, A. Duggal11, H.R. Büller2, T.-F. Wang6, D.A. Garcia12, G.E. Raskob13, N. van Es2

  • Abstract Number: PB0104

    Risk Factors for Non-variceal Hemorrhage in Patients with Chronic Liver Disease

    P. Kesavan1, A. Afzal1, S. Luo1,2, B. Gage1, M. Schoen2, K. Sanfilippo1,2

  • Abstract Number: PB1130

    Risk Factors for Reccurence of Catheter Related upper Extremity Deep Venous Thrombosis in Cancer Patients

    R. Hakem1, S. Soudet1, M.A. Sevestre1

  • Abstract Number: PB1052

    Risk Factors for Recurrent Thrombosis and Cause of Death in Patients with Antiphospholipid Syndrome; A Swedish Cohort Study

    N. Karandyszowska1, H. Alagündüz1, J. Oesman1, M. Magnusson2, E. Svenungsson3, A. Antovic3, M. Bruzelius1

  • Abstract Number: PB1102

    Risk Factors for Symptomatic Venous Thromboembolism in Children and Adolescents with Lymphomas

    D. Evstratov1, P. Zharkov1, N. Myakova1

  • Abstract Number: PO120

    Risk Factors for Venous Thromboembolism at the University College Hospital, Ibadan

    W. Shokunbi1, P. Ogundeji1, O. Aworanti1, C. Akunwata1

  • Abstract Number: PB1129

    Risk Factors of Catheter-related Thrombosis in Patients with Multiple Myeloma Undergoing Autologous Stem Cell Transplantation

    A. Hoppe1, J. Rupa-Matysek1, B. Malecki1, D. Dytfeld1, L. Gil1

  • Abstract Number: PB1204

    Risk Factors of Venous Thromboembolism at Patients with Endoscopic Urological Interventions

    D. Shorikova1, E. Shorikov1, P. Shorikov1

  • Abstract Number: PB0330

    Risk of Misdiagnosis for Patients Presenting the Closed Variants E1359K or V1360A in Exon 28 of VWF due to a Major Discordance on VWF Activity Results between the VWF:GpIbM and VWF:GpIbR Assays

    F. Lassalle1, E. Jeanpierre1, C. Zawadzki1, C. Pouymayou2, S. Castet3, Y. Huguenin3, R. Marlu4, A. Voyer5, P. Chamouni6, J. Goudemand1, S. Susen1

  • Abstract Number: PB1113

    Risk of Vascular Occlusive Events with PARPis in Cancer: A Systematic Review and Meta-analysis

    H. Haguet1, L. Ronvaux1, J. Douxfils1,2

  • Abstract Number: OC 23.2

    Risk of Venous and Arterial Thromboembolic Events in Patients Receiving Targeted Anti-cancer Therapy – A Nationwide Cohort Study

    F. Moik1, C. Ay1, E. Horváth-Puhó2, I. Pabinger1, F. Mulder3, N. van Es3, H.T. Sørensen2

  • Abstract Number: PB1095

    Risk of Venous Thromboembolism and Major Bleeding in the Clinical Course of Osteosarcoma and Ewing Sarcoma Patients

    M.A.M. Stals1, F.HJ Kaptein1, R.E Evenhuis2, AJ Gelderblom3, M.V Huisman1, DSA Karis2, RWD Noten1, SC Cannegieter1,4, HH Versteeg1, MAJ van de Sande2, FA Klok1

  • Abstract Number: OC 76.1

    Rivaroxaban for the Treatment of Symptomatic Isolated Distal Deep Vein Thrombosis – RIDTS Study

    W. Ageno1, L. Bertù1, E. Bucherini2, G. Camporese3, F. Dentali1, M. Iotti4, G. Lessiani5, R. Parisi6, P. Prandoni7, M. Sartori8, A. Visonà9, G. Palareti7, RIDTS study group

  • Abstract Number: PB1062

    Rivaroxaban versus Vitamin K Antagonist for the Secondary Prevention of Recurrent Thrombosis in Antiphospholipid Syndrome: A Systematic Review and Meta-analysis

    R.D. Agustin1, D.L. Villanueva1, E. Alajar1, M.T. Abola1

  • Abstract Number: PB0219

    Role of Endothelium Activation Biomarkers in Prediction COVID-19 Related Intra-hospital Mortality

    M. Marchetti1, P. Gomez-Rosas2,1, L. Russo1, E. Sanga1, S. Gamba1, C. Verzeroli1, F. Restuccia1, F. Schieppati1, E. Bonanomi1, M. Rizzi1, S. Fagiuoli1, A. D'Alessio3, L. Lorini1, A. Falanga1,4

  • Abstract Number: PB0305

    Role of Hematological Parameters in Stratification of Covid-19 Disease Severity

    S. Taj1, A. Kashif1, S. Arzinda Fatima1, S. Imran1, A. Lone1, Q. Ahmed1

  • Abstract Number: PB1150

    Role of Individual Venous Symptoms and Signs at Baseline in Predicting Future Development of Post-thrombotic Syndrome: Sub-analysis of the ATTRACT Trial

    F. Rinfret1,2, C.-S. Gu3, S. Vedantham4, S. Kahn2,1

  • Abstract Number: PB1159

    Role of Inherited Thrombophilia in the Occurrence of Arterial Thrombosis after Venous Thromboembolism

    A. Ciavarella1,2, M. Abbattista1, F. Gianniello1, M. Capecchi1,2, A. Artoni1, I. Martinelli1, F. Peyvandi1,3

  • Abstract Number: LPB0097

    Role of Low-dose Aspirin on the Release of Circulating Microvesicles in Patients at Cardiovascular Risk with and without Type 2 Diabetes

    P. Simeone1, R. Liani1, R. Tripaldi1, S. Ciotti1, P. Lanuti1, M. Marchisio1, S. Miscia1, F. Santilli1

  • Abstract Number: PB0986

    Role of Platelet GARP in TGFβ Activation

    J. Bodart1, C. Dufeys1, Y. Senis2, Z. Nagy3, L. Bertrand1, C. Beauloye1,4, S. Lucas5, S. Horman1

  • Abstract Number: PB0982

    Role of Platelet HIF-2 Alpha to Indorse Thrombogenicity through Synthesis of PAI-1 during Hypoxia

    R.L. Mallick1, S.N. Chaurasia2, D. Dash2, P. Mallick3

  • Abstract Number: PB0981

    Role of Platelet’s Heme Oxygenase-1 in Obese Patients with and without Type 2 Diabetes Mellitus

    R. Liani1, P.G. Simeone1, R. Tripaldi1, S. Ciotti1, P. Lanuti1, G. Bologna1, A. Boccatonda1, D. D'Ardes1, V. Luca2, F. Santilli1

  • Abstract Number: OC 02.4

    Role of Shear Stress and tPA Concentration in the Fibrinolytic Potential of Thrombi

    C. Whyte1, A. Mostefai1, K.M Baeten1, A.J Lucking2, D.E Newby2, N.A Booth1, N.J Mutch1

  • Abstract Number: PB0865

    Role of Soluble C5b-9 (sC5b-9) in Dosing Adjustments of Anti-complement Therapy during Pregnancy in a Patient with History of Atypical Hemolytic Uremic Syndrome (aHUS)

    C. Dos Santos1, G. Greloni2, M.F. Alberto3, A. Sánchez-Luceros3

  • Abstract Number: LPB0018

    Role of the “Mobile Loop” (Residues 142-150) in the Intrinsic Instability of TAFIa

    H. Marier1, M. Boffa1

  • Abstract Number: OC 42.1

    Role of the Coagulation Factor XIII Binding Site on Crosslinking of Fibrinogen αC (233 – 425)

    F.D. Ablan1, M. Hindi1, M. Maurer1

  • Abstract Number: PB0022

    Role of the Interaction between Thrombophilia and Other Risk Factors in the Occurring of Ischemic Stroke in Young Patients: Algerian Restrospective Study about 75 Cases

    M. El Horri1, I. Khachaa1, A. Chikh Khelifa1, A. Berrah1, M. Chekkal2, F. Bemmoussat1, L. Benmahdi1, S.E. Belakehal1

  • Abstract Number: LPB0023

    Role of Tissue Factor in Delayed Bone Repair Induced by Diabetic State in Mice

    K. Tatsumi1,2, H. Ehara2, Y. Takafuji2, N. Kawao2, M. Ishida2, K. Okada2, N. Mackman3, M. Shima1, H. Kaji2

  • Abstract Number: PB1107

    Role of Tissue Factor in the Procoagulant Shift of Endothelial Cells upon Exposure to Cancer Cell-derived Microparticles

    R. Djedidi-Amrane1,2, P. Vandreden2, G. Gerotziafas1,3,4

  • Abstract Number: PB0233

    Rotational Thromboelastometry (ROTEM) Profiling of COVID–19 Patients

    M. Mitrovic1,2, N. Sabljic1, Z. Svetkovic3,2, N. Pantic1, Z. Bukumiric4, N. Savic5, B. Milenkovic6,2, M. Virijevic1,2, Z. Pravdic1, N. Suvajdzic1,2, J. Fareed7, D. Antic1,2

  • Abstract Number: PB0706

    ROTEM in Combination with Bleeding History – Can it Serve as a Screening Test for Factor XIII Deficiency in Patients with Suspected Bleeding Disorder?

    T. Geevar1, R.G. Dave1, T. David V1, G. K C1, R. Vijayan1, A. Samuel1, S. Singh1, J. John Mammen1, S. Chandran Nair1

  • Abstract Number: LPB0040

    rs2431697 of miR-146a Regulates NETosis Determining the Thickness of the Carotid Intima-media in Patients with Rheumatoid Arthritis

    L. Reguilón Gallego1, A.M. del los Reyes-García1, S. Águila1, M.P. Fernández-Pérez1, N. García Barberá1, L. Zapata-Martínez1, I. Ruiz Lorente1, M.C. Ábalos-Aguilera2, E. Saiz3, M.F. Pina3, M.T. Herranz4, A. Barceló5, I. Hervés5, V. Vicente1, C. López-Pedrera2, C. Martínez1, R. González-Conejero1

  • Abstract Number: PB0439

    Rutin Succinate Acts as an Anticoagulant and Inhibits Snake Venom Metalloproteinases in an Acute Thrombo-hemorrhagic Disorder Model

    A.T.A. Sachetto1, M.L. Santoro1

Jump to:  View All • a b c d e f g h i j k l m n o p q [r] s t u v w x y z
  • Help & Support
  • About Us
  • Cookies & Privacy
  • Wiley Job Network
  • Terms & Conditions
  • Advertisers & Agents
Copyright © 2022 John Wiley & Sons, Inc. All Rights Reserved.
Wiley